Moreover, as this study has demonstrated a synergistic effect of combining olaparib and doxorubicin, combining PARP inhibition with a conventional genotoxic anti-cancer agents might be beneficial in the treatment of osteosarcoma patients. Here, PARP1 is linked to cancer.